CAR T cell News and Research

RSS

Arresting tumor growth for a variety of cancers through T cell engineering

Through T cell engineering, researchers at Virginia Commonwealth University Massey Cancer Center show that it's possible to arrest tumor growth for a variety of cancers and squash the spread of cancer to other tissues.

30 Apr 2021

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer

Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of the United States.

29 Apr 2021

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced

The National Comprehensive Cancer Network and the NCCN Foundation today announced six new recipients for the 2021 NCCN Foundation Young Investigator Awards Program.

15 Apr 2021

Experts to discuss advanced cancer cell and gene therapies at Summit 2021

April 29 marks a pivotal moment in cancer research when the world's brightest minds come together to discuss how to translate the success of CAR T-cell therapies for blood cancers into successful cell and gene therapies for the most complex and deadly solid tumor cancers.

15 Apr 2021

New research could rescue failed immunotherapies for treating solid tumors

New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.

7 Apr 2021

Stem cell transplants offer long-term benefits for pediatric cancer patients receiving immunotherapy

Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds.

1 Apr 2021

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

25 Mar 2021

New therapeutic vaccine uses patient's own tumor cells to aid in cancer destruction

Immunotherapy, which recruits the body's own immune system to attack cancer, has given many cancer patients a new avenue to treat the disease.

24 Mar 2021

Study explores how CAR T immunotherapy could be used to treat solid tumors

A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumors in addition to leukemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future.

18 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

An innovative cell-based treatment for cancer has been found promising for the control of infections caused by fungi.

4 Mar 2021

PICI awards $3 million to support early career cancer researchers

From improving immunotherapy response in childhood cancer patients, to better understanding how cancer's spread to the liver affects the body's immune system, to helping T cells stay energized to fight cancer, The Parker Institute for Cancer Immunotherapy (PICI)'s 2021 class of early career researchers award recipients are pursuing ideas that have the potential to change the face of oncology.

3 Mar 2021

ACGT awards $500,000 to advance immunotherapy approach for treating solid tumors

A scientific team led by Brian Brown, PhD, Professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has been awarded $500,000 from Alliance for Cancer Gene Therapy to advance a promising immunotherapy approach to fight lung cancer and other solid tumor cancers.

1 Mar 2021

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

24 Feb 2021

Understanding the dynamics of brain blood flow could hold key for treating neurologic conditions

While the human brain has over 400 miles of total vasculature, little is known about the tiny capillaries that make up much of this intricate labyrinth of blood vessels critical for delivering oxygenated blood and nutrients to billions of brain cells.

19 Feb 2021

Study reveals extremely low detection of SARS-CoV-2 on surfaces in oncology facilities

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.

18 Feb 2021

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

Researchers evaluate frequency of SARS-CoV-2 in hematology/oncology settings

18 Feb 2021

MSK researchers report an underlying cause of COVID brain

One of the dozens of unusual symptoms that have emerged in COVID-19 patients is a condition that's informally called "COVID brain" or "brain fog."

9 Feb 2021

CAR T cell News and Research

Arresting tumor growth for a variety of cancers through T cell engineering

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer

New recipients for the 2021 NCCN Foundation Young Investigator Awards announced

Experts to discuss advanced cancer cell and gene therapies at Summit 2021

New research could rescue failed immunotherapies for treating solid tumors

Stem cell transplants offer long-term benefits for pediatric cancer patients receiving immunotherapy

First cell-based gene therapy approved by the FDA for treating multiple myeloma

Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy

New therapeutic vaccine uses patient's own tumor cells to aid in cancer destruction

Study explores how CAR T immunotherapy could be used to treat solid tumors

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Innovative cancer treatment effective in combating fungal infection in vitro and in mice

PICI awards $3 million to support early career cancer researchers

ACGT awards $500,000 to advance immunotherapy approach for treating solid tumors

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

Understanding the dynamics of brain blood flow could hold key for treating neurologic conditions

Study reveals extremely low detection of SARS-CoV-2 on surfaces in oncology facilities

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Researchers evaluate frequency of SARS-CoV-2 in hematology/oncology settings

MSK researchers report an underlying cause of COVID brain

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News